Inmunoterapia "STAb" para el tratamiento de neoplasias hematológicas

  1. RAMÍREZ FERNÁNDEZ, ÁNGEL
Dirixida por:
  1. Belén Blanco Durango Director
  2. Luis Álvarez Vallina Director

Universidade de defensa: Universidad Complutense de Madrid

Fecha de defensa: 06 de xullo de 2022

Tribunal:
  1. José Ramón Regueiro González-Barros Presidente
  2. Joaquín Martínez López Secretario
  3. Silvia Martin-Lluesma Vogal
  4. Natalia Gómez Lozano Vogal
  5. Francisco Martín Molina Vogal

Tipo: Tese

Teseo: 810708 DIALNET lock_openDocta Complutense editor

Resumo

Cancer immunotherapy has progressed significantly with the emergence of potentially curative strategies for B-cell acute lymphoblastic leukemia (B-ALL). The most effective approaches are based on the use of anti-CD19 x anti-CD3 bispecific antibodies,and adoptive cell therapies with engineered T lymphocytes expressing a chimeric antigen receptor (CAR) that recognizes the CD19 molecule (CAR-T19). The administration of CAR-T19 cells and the systemic infusion of anti-CD19 x anti-CD3 bispecific T cell engagers (BiTEs) have demonstrated a remarkable response rate in patients with refractory or relapsed B-ALL (R/R B-ALL). However, despite the excellent results reported, 30-60% of treated patients relapse or progress within one year of treatment. In our laboratory, we have developed the immunotherapy STAb (Secretion of T cell redirecting bispecific Antibodies)-T, which consists of the modification of T cells to secrete T cell engagers (TCEs)...